Translation: Original published in Finnish on 8/19/2026 at 7:00 am EEST.

Nightingale Health announced on Tuesday that it has partnered with Supernormal, a Finnish provider of medical weight loss services. With the agreement, Nightingale's at-home blood test (Remote Health Check) will be integrated into Supernormal's treatment programs, where customers' metabolic health is monitored, for example, during GLP-1 medication. While the news is a positive indication of commercial demand for the technology, we estimate that the financial impact of the agreement will remain minor for now.

According to the company, Supernormal has over 10,000 members, and the utilization of tests before and during treatment inherently creates recurring sample demand for Nightingale. The rapid adoption of GLP-1 drugs has created a need in healthcare to verify the broader health benefits of weight loss. In our view, Nightingale's cost-effective and comprehensive blood analysis is an excellent fit for this purpose. While the volumes generated by the Supernormal collaboration alone do not change Nightingale's overall financial picture, the collaboration serves as a good reference for similar international clinics, which may be significantly larger in scale. As we have emphasized before, the scalability of Nightingale's business model and the turnaround in profitability require the company to establish numerous healthcare partnerships and consistently increase their volumes over the long term.